SCHEMBL21135447

SCHEMBL21135447

OC[C@@H]1CCCN(c2ccccc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.52
PTPN1 P18031 1/20 0.50
HTT P42858 2/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
NOTUM Q6P988 1/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
MAP4K4 O95819 1/20 0.44
TYMP P19971 2/20 0.43
MBTD1 Q05BQ5 1/20 0.42
L3MBTL3 Q96JM7 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CNR1 P21554 1/20 0.42
EPHX2 P34913 1/20 0.42
MMP2 P08253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6648521 1.00 CYP2D6 (0.52) CYP2D6PTPN1HTTPOLBKMT2A
SCHEMBL21135739 1.00 CYP2D6 (0.52) CYP2D6PTPN1HTTPOLBKMT2A
SCHEMBL720691 0.89 NOTUM (0.54) CYP2D6NOTUMALDH1A1MAPTMBTD1
SCHEMBL25855629 0.85 ESR1 (0.45) CYP2D6PTPN1HTTPOLBKMT2A
SCHEMBL21135458 0.83 NOTUM (0.49) CYP2D6HTTKMT2ANOTUMALDH1A1
SCHEMBL21135466 0.83 CYP3A4 (0.56) NOTUMNPC1RAB9AALDH1A1MAPT
SCHEMBL6271445 0.83 NOTUM (0.49) CYP2D6HTTKMT2ANOTUMALDH1A1
SCHEMBL7790528 0.83 EPHX2 (0.51) CYP2D6PTPN1RAB9AMAP4K4TYMP
SCHEMBL77035 0.83 KDM4E (0.49) CYP2D6PTPN1HTTPOLBKMT2A
SCHEMBL21135496 0.83 NOTUM (0.49) CYP2D6HTTKMT2ANOTUMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3371196-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION UNIV MONTREAL (CA) 2021-10-27 EP disclosed
US-10329307-B2 Heterocyclic compounds as inhibitors of platelet aggregation UNIVERSITE DE MONTREAL (CA) 2019-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329307-B2 Heterocyclic compounds as inhibitors of platelet aggregation F12, F2, F3 CYP2D6 221/4885PTPN1 497/4885HTT 2643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.